Inovio Pharma (INO) Misses Q1 EPS by 2c

Inovio Pharma (NASDAQ: INO) reported Q1 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $199 thousand versus the consensus estimate of $670 thousand.

As of March 31, 2022, cash and cash equivalents and short-term investments were $360.4 million compared to $401.3 million as of December 31, 2021. As of March 31, 2022, the Company had 226.5 million common shares outstanding and 247.8 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Inovio Pharma (INO) Tops Q2 EPS by 18c
• Stantec (STN) Tops Q2 EPS by 47c